Moderna and Merck cancer vaccine used with Keytruda reduces risk of deadly skin cancer spreading – CNBC June 5, 2023
Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23 – Endpoints News June 5, 2023
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano – Moderna Investor Relations April 16, 2023
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano – news.modernatx.com April 16, 2023
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer – Merck March 1, 2023
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients – Moderna Investor Relations February 22, 2023
J&J and Merck Ebola vaccines produce lasting antibodies in children and adults December 15, 2022December 14, 2022
J&J and Merck Ebola vaccines produce lasting antibodies in children and adults December 15, 2022December 14, 2022
Positive Moderna, Merck cancer vaccine data advances mRNA promise, shares rise December 13, 2022December 13, 2022